Literature DB >> 23777464

From lipoproteins to chondrocytes: a brief summary of the European Medicines Agency's regulatory guidelines for advanced therapy medicinal products.

Sadik H Kassim1, Robert P T Somerville.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23777464      PMCID： PMC3689154          DOI： 10.1089/hum.2013.101

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN： 1043-0342            Impact factor:   5.695


× No keyword cloud information.
  1 in total

1.  Clinical development of advanced therapy medicinal products in Europe: evidence that regulators must be proactive.

Authors:  Romaldas Maciulaitis; Lucia D'Apote; Andrew Buchanan; Laura Pioppo; Christian K Schneider
Journal:  Mol Ther       Date:  2012-03       Impact factor: 11.454
  1 in total
  1 in total

1.  Re-examination of regulatory opinions in Europe: possible contribution for the approval of the first gene therapy product Glybera.

Authors:  Natsumi Watanabe; Kazuo Yano; Kenichiro Tsuyuki; Teruo Okano; Masayuki Yamato
Journal:  Mol Ther Methods Clin Dev       Date:  2015-02-11       Impact factor: 6.698
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.